152 related articles for article (PubMed ID: 38161257)
1. Surface Engineering of Natural Killer Cells with CD44-targeting Ligands for Augmented Cancer Immunotherapy.
Kim S; Li S; Jangid AK; Park HW; Lee DJ; Jung HS; Kim K
Small; 2024 Jun; 20(24):e2306738. PubMed ID: 38161257
[TBL] [Abstract][Full Text] [Related]
2. Optimized Design of Hyaluronic Acid-Lipid Conjugate Biomaterial for Augmenting CD44 Recognition of Surface-Engineered NK Cells.
Park HW; Lee W; Kim S; Jangid AK; Park J; Lee CE; Kim K
Biomacromolecules; 2024 Mar; 25(3):1959-1971. PubMed ID: 38379131
[TBL] [Abstract][Full Text] [Related]
3. Tailoring tumor-recognizable hyaluronic acid-lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells.
Lee CE; Kim S; Park HW; Lee W; Jangid AK; Choi Y; Jeong WJ; Kim K
Nano Converg; 2023 Dec; 10(1):56. PubMed ID: 38097911
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.
Qhattal HS; Hye T; Alali A; Liu X
ACS Nano; 2014 Jun; 8(6):5423-40. PubMed ID: 24806526
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
6. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
7. Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities.
Kim S; Kim K
Biomater Adv; 2022 Sep; 140():213059. PubMed ID: 35961186
[TBL] [Abstract][Full Text] [Related]
8. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
9. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
Jochems C; Hodge JW; Fantini M; Fujii R; Morillon YM; Greiner JW; Padget MR; Tritsch SR; Tsang KY; Campbell KS; Klingemann H; Boissel L; Rabizadeh S; Soon-Shiong P; Schlom J
Oncotarget; 2016 Dec; 7(52):86359-86373. PubMed ID: 27861156
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
Ganesh S; Iyer AK; Morrissey DV; Amiji MM
Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell engineering - a new hope for cancer immunotherapy.
Lin CY; Gobius I; Souza-Fonseca-Guimaraes F
Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912
[TBL] [Abstract][Full Text] [Related]
13. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
14. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
16. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
17. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
18. Engineered Metal-Phenolic Capsules Show Tunable Targeted Delivery to Cancer Cells.
Ju Y; Cui J; Sun H; Müllner M; Dai Y; Guo J; Bertleff-Zieschang N; Suma T; Richardson JJ; Caruso F
Biomacromolecules; 2016 Jun; 17(6):2268-76. PubMed ID: 27249228
[TBL] [Abstract][Full Text] [Related]
19. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
Wei X; Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
